ALEC - Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs | Benzinga
SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the Company's TREM2 and progranulin (PGRN) programs. The events will include presentations from Alector's management as well as leading scientific and clinical experts who will provide their perspectives on the biological and genetic rationale for the TREM2 and PGRN targets, share an overview of the current treatment landscapes for frontotemporal dementia and Alzheimer's disease, and discuss the significant unmet needs that remain in the treatment of these neurodegenerative diseases.
Details of the webinars are as follows:
Diving Deep into TREM2: Uncovering its Potential as a Therapeutic Target for Alzheimer's Disease
December 7, 2023, from 12:00 pm - 1:30 pm Eastern Standard Time (EST)
Alector's management team will be joined by:
- Michael Heneka, M.D., Director of the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg and Adjunct Professor at the University of Massachusetts Chan Medical School
- Reisa Sperling, M.D., Professor of Neurology at Harvard Medical School and Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital and Massachusetts General Hospital
A ...